Results of Annual General Meeting
Released
Released
Announcement PDF
Race Oncology Ltd • ABN 61 149 318 749
L36, 1 Macquarie Place Sydney NSW 2000 • T. +61 2 8051 3043 • E. info@raceoncology.com • www.raceoncology.com
ASX Announcement
Results of Annual General Meeting
24 November 2025 – Race Oncology Limited (“Race”) advises that its Annual General Meeting of
Shareholders was held today at 12.00 pm AEDT.
The resolutions were voted in accordance with the Notice of Annual General Meeting previously advised
to the Australian Securities Exchange.
All resolutions were carried on a poll.
Further information required by section 251AA(2) of the Corporations Act 2001 (Cth) is attached to this
announcement.
-ENDS-
About Race Oncology (ASX: RAC)
Race Oncology (ASX: RAC) is an ASX-listed Phase 3 clinical biopharmaceutical company with a dedicated
mission to be at the heart of cancer care.
Race’s leadasset, RCDS1 (E,E-bisantrene), is a small molecule anticancer agent that primarily functions via
G4-DNA & RNA binding, leading topotent inhibition of theimportant cancer growthregulator MYC.RCDS1
has demonstrated therapeutic activity in cancer patients with a well characterised safety profile. Recent
discoveries have enabled composition of matter IP filings that may provide for 20 years of patent
protection over RCDS1.
Raceis advancing a proprietaryformulation of RCDS1 (RC220) toaddress thehigh unmet needs of patients
across multiple oncology indications, with a Phase 3 clinical program in acute myeloid leukaemia (AML), a
Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm
NSCLC), and a Phase 1a/b programin combination with the anthracyclinedoxorubicin where theaim is to
deliver both cardioprotection and enhanced anticancer activity for solid tumour patients.
Race Oncology has collaborated with Astex, MD Anderson, Sheba City of Health, UNC School of Medicine,
University of Wollongong and University of Newcastle, and is actively exploring partnerships, licence
agreements or a commercial merger and acquisition to accelerate access to RC220 for patients with
cancer across the world.
Learn more at www.raceoncology.com.
If you have any questions on this announcement or any past RaceOncology announcements, please go to
the Interactive Announcements page at https://announcements.raceoncology.com
Release authorised by:
Board of Race Oncology
info@raceoncology.com
Media contact:
Jane Lowe +61 411 117 774
jane.lowe@irdepartment.com.au
Disclosure of Proxy Votes
Race Oncology Limited
Annual General Meeting
Monday, 24 November 2025
In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.
Automic
GPO Box 5193, Sydney, NSW 2001
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)
F +61 (0)2 8583 3040 E hello@automic.com.au
ABN 27 152 260 814
Proxy Votes
Poll Results (if
applicable)
Results
Resolution
Decided by
Show of
Hands (S) or
Poll (P)
Total Number of
Proxy Votes
exercisable by
proxies validly
appointed
FOR AGAINST ABSTAIN
PROXY'S
DISCRETION
FOR AGAINST ABSTAIN OUTCOME
1 ADOPTION OF REMUNERATION REPORT P 37,811,513
36,798,087
97.32%
188,274
0.50%
226,485
825,152
2.18%
45,972,556
99.59%
188,274
0.41%
226,485 -
2 ELECTION OF DIRECTOR – DR MEGAN BALDWIN P 51,820,526
46,752,700
90.22%
3,496,559
6.75%
3,485,087
1,571,267
3.03%
54,555,712
92.36%
4,512,178
7.64%
4,587,040 Carried
3 RE-ELECTION OF DIRECTOR – DR PETER SMITH P 55,097,613
54,239,739
98.44%
32,722
0.06%
208,000
825,152
1.50%
63,414,208
99.95%
32,722
0.05%
208,000 Carried
4 ISSUE OF INCENTIVE OPTIONS TO DR MEGAN
BALDWIN
P 34,112,873
28,790,223
84.40%
3,721,383
10.91%
3,548,507
1,601,267
4.69%
35,075,791
88.57%
4,527,069
11.43%
4,650,460 Carried
5 ISSUE OF INCENTIVE OPTIONS TO DR SERGE
SCROFANI
P 37,374,101
36,435,304
97.49%
83,645
0.22%
287,279
855,152
2.29%
43,882,396
99.81%
83,645
0.19%
287,279 Carried
6 ISSUE OF INCENTIVE OPTIONS TO DR PETER
SMITH
P 37,419,571
36,512,274
97.58%
83,645
0.22%
241,809
823,652
2.20%
43,927,866
99.81%
83,645
0.19%
241,809 Carried
7 ISSUE OF OPTIONS IN LIEU OF BONUS
ENTITLEMENTS – DR PETER SMITH
P 37,419,571
36,522,888
97.60%
73,031
0.20%
241,809
823,652
2.20%
43,938,480
99.83%
73,031
0.17%
241,809 Carried
8 ISSUE OF OPTIONS IN LIEU OF BONUS
ENTITLEMENTS – DR DANIEL TILLETT
P 37,419,571
36,535,453
97.64%
60,466
0.16%
241,809
823,652
2.20%
43,833,895
99.86%
60,466
0.14%
358,959 Carried
Proxy Votes
Poll Results (if
applicable)
Results
Resolution
Decided by
Show of
Hands (S) or
Poll (P)
Total Number of
Proxy Votes
exercisable by
proxies validly
appointed
FOR AGAINST ABSTAIN
PROXY'S
DISCRETION
FOR AGAINST ABSTAIN OUTCOME
9 REPLACEMENT OF CONSTITUTION P 54,979,788
53,519,679
97.34%
525,708
0.96%
325,825
934,401
1.70%
62,432,680
99.16%
525,708
0.84%
696,542 Carried
10 CHANGE OF COMPANY NAME P 52,353,857
49,932,710
95.38%
1,434,447
2.74%
2,951,756
986,700
1.88%
58,578,373
96.50%
2,124,801
3.50%
2,951,756 Carried
Share your feedback
Discover